The mutation of the IDH gene results in the conversion of α-ketoglutarate into 2-hydroxyglutaric acid, which inhibits tumour angiogenesis by inhibiting hypoxia inducible factor 1α [28, 29]. The gene discussed is IDH2; the disease is neoplasm.